NASDAQ:DRNA

Dicerna Pharmaceuticals Stock Forecast, Price & News

$28.96
+0.43 (+1.51 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$28.84
Now: $28.96
$30.39
50-Day Range
$22.91
MA: $26.51
$29.51
52-Week Range
$16.50
Now: $28.96
$29.90
Volume761,983 shs
Average Volume818,360 shs
Market Capitalization$2.21 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.33
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Dicerna Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DRNA
CUSIPN/A
Phone617-621-8097
Employees302
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$23.90 million
Book Value$2.22 per share

Profitability

Net Income$-120,460,000.00

Miscellaneous

Market Cap$2.21 billion
Next Earnings Date5/6/2021 (Estimated)
OptionableOptionable

Headlines

Interesting DRNA Call Options For June 18th
April 16, 2021 |  nasdaq.com
Royalty Pharma Buys Dicerna's Royalty Interest In OXLUMO
April 8, 2021 |  markets.businessinsider.com
Recap: Dicerna Pharmaceuticals Q4 Earnings
February 25, 2021 |  finance.yahoo.com
See More Headlines

MarketRank

Overall MarketRank

1.96 out of 5 stars

Medical Sector

70th out of 2,025 stocks

Pharmaceutical Preparations Industry

28th out of 772 stocks

Analyst Opinion: 4.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$28.96
+0.43 (+1.51 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DRNA News and Ratings via Email

Sign-up to receive the latest news and ratings for DRNA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Dicerna Pharmaceuticals (NASDAQ:DRNA) Frequently Asked Questions

Is Dicerna Pharmaceuticals a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Dicerna Pharmaceuticals in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Dicerna Pharmaceuticals stock.
View analyst ratings for Dicerna Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Dicerna Pharmaceuticals?

Wall Street analysts have given Dicerna Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Dicerna Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Dicerna Pharmaceuticals' next earnings date?

Dicerna Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Dicerna Pharmaceuticals
.

How were Dicerna Pharmaceuticals' earnings last quarter?

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) posted its earnings results on Thursday, February, 25th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.11 by $0.60. The biopharmaceutical company had revenue of $40.96 million for the quarter, compared to analyst estimates of $81.82 million. Dicerna Pharmaceuticals had a negative net margin of 88.81% and a negative trailing twelve-month return on equity of 71.72%.
View Dicerna Pharmaceuticals' earnings history
.

How has Dicerna Pharmaceuticals' stock been impacted by COVID-19?

Dicerna Pharmaceuticals' stock was trading at $16.88 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, DRNA shares have increased by 71.6% and is now trading at $28.96.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for DRNA?

7 analysts have issued 1-year price objectives for Dicerna Pharmaceuticals' shares. Their forecasts range from $33.00 to $48.00. On average, they anticipate Dicerna Pharmaceuticals' stock price to reach $39.14 in the next year. This suggests a possible upside of 35.2% from the stock's current price.
View analysts' price targets for Dicerna Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Dicerna Pharmaceuticals' key executives?

Dicerna Pharmaceuticals' management team includes the following people:
  • Dr. Douglas M. Fambrough III, Co-Founder, CEO, Pres & Director (Age 52, Pay $937.43k)
  • Dr. Bob D. Brown, Exec. VP of R&D and Chief Scientific Officer (Age 56, Pay $671.96k)
  • Dr. Ralf H. Rosskamp, Consultant (Age 68, Pay $707.13k)
  • Mr. Robert D. Ciappenelli M.B.A., Chief Commercial Officer (Age 54, Pay $339.51k)
  • Dr. Mark Behlke, Co-Founder & Member of Scientific Advisory Board
  • Prof. John J. Rossi, Co-Founder & Chairman of Scientific Advisory Board (Age 74)
  • Mr. Douglas W. Pagan, Chief Financial Officer (Age 49)
  • Mr. James B. Weissman, Exec. VP & COO (Age 59)
  • Ms. Ling Zeng J.D., Chief Legal Officer & Sec.
  • Ms. Regina DeTore Paglia, Chief HR Officer

What is Douglas M. Fambrough, Ph.D.'s approval rating as Dicerna Pharmaceuticals' CEO?

35 employees have rated Dicerna Pharmaceuticals CEO Douglas M. Fambrough, Ph.D. on Glassdoor.com. Douglas M. Fambrough, Ph.D. has an approval rating of 99% among Dicerna Pharmaceuticals' employees. This puts Douglas M. Fambrough, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Dicerna Pharmaceuticals' key competitors?

What other stocks do shareholders of Dicerna Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dicerna Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Strongbridge Biopharma (SBBP), Amarin (AMRN), Exelixis (EXEL), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS), Gilead Sciences (GILD), Pfizer (PFE) and Advanced Micro Devices (AMD).

What is Dicerna Pharmaceuticals' stock symbol?

Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA."

Who are Dicerna Pharmaceuticals' major shareholders?

Dicerna Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include TrimTabs Asset Management LLC (0.02%), DnB Asset Management AS (0.02%) and Pacer Advisors Inc. (0.00%). Company insiders that own Dicerna Pharmaceuticals stock include Adam Koppel, Bain Capital Life Sciences Inv, Bob D Brown, Douglas Fambrough, James B Weissman, John B Green, Peter Kolchinsky and Regina M Paglia.
View institutional ownership trends for Dicerna Pharmaceuticals
.

Which major investors are selling Dicerna Pharmaceuticals stock?

DRNA stock was sold by a variety of institutional investors in the last quarter, including DnB Asset Management AS, and Pacer Advisors Inc.. Company insiders that have sold Dicerna Pharmaceuticals company stock in the last year include Adam Koppel, Bob D Brown, James B Weissman, John B Green, and Regina M Paglia.
View insider buying and selling activity for Dicerna Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Dicerna Pharmaceuticals stock?

DRNA stock was bought by a variety of institutional investors in the last quarter, including TrimTabs Asset Management LLC.
View insider buying and selling activity for Dicerna Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Dicerna Pharmaceuticals?

Shares of DRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Dicerna Pharmaceuticals' stock price today?

One share of DRNA stock can currently be purchased for approximately $28.96.

How much money does Dicerna Pharmaceuticals make?

Dicerna Pharmaceuticals has a market capitalization of $2.21 billion and generates $23.90 million in revenue each year. The biopharmaceutical company earns $-120,460,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis.

How many employees does Dicerna Pharmaceuticals have?

Dicerna Pharmaceuticals employs 302 workers across the globe.

What is Dicerna Pharmaceuticals' official website?

The official website for Dicerna Pharmaceuticals is www.dicerna.com.

Where are Dicerna Pharmaceuticals' headquarters?

Dicerna Pharmaceuticals is headquartered at 33 HAYDEN AVENUE, LEXINGTON MA, 02421.

How can I contact Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals' mailing address is 33 HAYDEN AVENUE, LEXINGTON MA, 02421. The biopharmaceutical company can be reached via phone at 617-621-8097 or via email at [email protected]


This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.